News

Friday May 27, 2022

Result of Annual General Meeting and Strategy Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Result of Annual General Meeting and Strategy Update Brighton, United Kingdom – 27 May 2022 – Destiny Pharma plc (AIM: DEST), a […]

Thursday May 26, 2022

Destiny Pharma plc Board changes

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma appoints three Non-Executive Directors Brighton, United Kingdom – 26 May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage innovative […]

Thursday May 12, 2022

Landmark NTCD-M3 data to be presented at Anaerobe

Destiny Pharma plc (“Destiny Pharma” or “the Company”) World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration Brighton, […]

Wednesday May 4, 2022

Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about h...

Destiny Pharma’s Chief Business Officer, Dr Stephanie Bewick, talks to @Labiotech-eu about her role, as part of the series ‘Chief Business Officers: Shedding Light on Biotech’s Dealmakers’. To read the […]

Tuesday May 3, 2022

Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – 3rd May […]